Viracta Therapeutics
#10530
Rank
$317.95K
Marketcap
United States
Country
Mr. Daniel R. Chevallard (CFO, COO & Sec.)
Dr. Lisa Rojkjaer (Chief Medical Officer)
Mr. Mark Andrew Rothera (CEO, Pres & Director)
Summary
History
Viracta Therapeutics was founded in 2019 to develop novel treatments for RNA viruses associated with multiple disease areas. The company is rapidly advancing its drug development program by leveraging its proprietary technologies to design small molecules that modulate RNA virus replication and translation.
Mission
Vision
Key Team
Dr. Susan Perrine M.D. (Scientific Founder and Consultant)
Dr. Robert M. Williams Ph.D. (Co-Founder)
Dr. Ronald J. Berenson M.D. (Co-Founder and Consultant)
Dr. Douglas V. Faller M.D., Ph.D. (Scientific Founder & Chairman of Scientific Advisory Board)
Mr. George Hillman (Co-Founder)
Dr. Thalia Papayannopoulou M.D. (Co-Founder)
Dr. Ayman El-Guindy (Chief Scientific Officer)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. Daniel R. Chevallard (CFO, COO & Sec.)
Dr. Lisa Rojkjaer (Chief Medical Officer)
Mr. Mark Andrew Rothera (CEO, Pres & Director)